<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109157">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765764</url>
  </required_header>
  <id_info>
    <org_study_id>192024-043</org_study_id>
    <nct_id>NCT01765764</nct_id>
  </id_info>
  <brief_title>Bimatoprost for the Treatment of Eyebrow Hypotrichosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of  bimatoprost solution  compared with
      vehicle in the treatment of eyebrow hypotrichosis (inadequate eyebrows).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants with at Least a 1-grade Increase (improvement) in the 4-point Global Eyebrow Assessment (GEBA) Scale</measure>
    <time_frame>Baseline, Month 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA)</measure>
    <time_frame>Baseline, Month 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Eyebrow Darkness as Measured Using DMSIA</measure>
    <time_frame>Baseline, Month 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 'Very Satisfied' or 'Mostly Satisfied' in Eyebrow Satisfaction Scale (ESS) Item #6</measure>
    <time_frame>Month 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Eyebrow Hypotrichosis</condition>
  <arm_group>
    <arm_group_label>Bimatoprost Solution BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimatoprost Solution QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle to Bimatoprost Solution BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost solution</intervention_name>
    <description>Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.</description>
    <arm_group_label>Bimatoprost Solution BID</arm_group_label>
    <arm_group_label>Bimatoprost Solution QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle to bimatoprost solution</intervention_name>
    <description>Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.</description>
    <arm_group_label>Bimatoprost Solution QD</arm_group_label>
    <arm_group_label>Vehicle to Bimatoprost Solution BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Mild to moderate eyebrow hypotrichosis (inadequate eyebrows)

        Exclusion Criteria:

          -  Patients with disease, infection, or abnormality of the eyebrow area

          -  Patients with permanent eyebrow loss due to over-grooming
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotrichosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
